Virani Shafique's Form 4 filing
Recursion Pharmaceuticals, Inc. (RXRX) · filed Jun 5, 2023
- Accession no.
- 0001209191-23-034601
- Filed
- Jun 5, 2023
- Trade date
- Jun 1-2, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $374.0K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Virani ShafiqueCIK 0001856081 | Officer (Chief Business Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 1, 2023 | Class A Common Stock | SSaleDisposed | −25,000 | $8.58 | −$214,500 | 161,819 | Direct | |
| Jun 2, 2023 | Class A Common Stock | SSaleDisposed | −17,865 | $8.93 | −$159,534.45 | 143,954 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.